University of Nebraska Medical Center

DigitalCommons@UNMC
Capstone Experience

Master of Public Health

12-2022

Urban/Rural Disparities of Thyroid Cancer Using the Integrated
Cancer Repository for Cancer Research (iCaRe2)
Sunita Regmi
University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/coph_slce
Part of the Epidemiology Commons

Recommended Citation
Regmi, Sunita, "Urban/Rural Disparities of Thyroid Cancer Using the Integrated Cancer Repository for
Cancer Research (iCaRe2)" (2022). Capstone Experience. 223.
https://digitalcommons.unmc.edu/coph_slce/223

This Capstone Experience is brought to you for free and open access by the Master of Public Health at
DigitalCommons@UNMC. It has been accepted for inclusion in Capstone Experience by an authorized
administrator of DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

1
Capstone Title: Urban/Rural Disparities of Thyroid Cancer Using the Integrated Cancer
Repository for Cancer Research (iCaRe2)

Sunita Regmi
MPH- Epidemiology Concentration

Chair Name, Credentials
Paraskevi A Farazi, PhD
Associate Professor, COPH, Department of Epidemiology

Member 2 Name, Credentials
Whitney S Goldner, MD
Professor, Division of Diabetes, Endocrinology and Metabolism

Member 3 Name, Credentials
Anupam Kotwal, MD
Assistant Professor, Division of Diabetes, Endocrinology and Metabolism

Member 4 Name, Credentials
Elizabeth Lyden, MS
Associate director, Instructor, COPH, Department of Biostatistics

2
Abstract:
Background and objective: Multiple studies have shown that the place of residence and the
distance to travel from one's residence to nearby health care providers impact cancer diagnosis
and treatment. The stage of cancer at the time of diagnosis is paramount for cancer treatment and
affects survival. Disparities in cancer treatment exist which affect the outcome disproportionately
to certain segments of the population. To date, much of the focus has been on the racial and
socioeconomic disparities in the management of thyroid cancer. The effect of geography and
location (urban-rural status) on thyroid cancer stage diagnosis has not been well studied.
Therefore, the purpose of this study was to- 1) To investigate geographic disparities in thyroid
cancer stage at the time of diagnosis. 2) To identify the factors affecting the stage of thyroid
cancer at the time of diagnosis.
Methods:
A cross-sectional study was conducted with the sample of 800 thyroid cancer patients using the
integrated Cancer data Repository for Cancer Research (iCaRe2) database. Residents in urban or
rural counties at the time of diagnosis were categorized by 2013 Rural-Urban Continuum Codes
and mapping between FIFS and Zip codes. The distance between the patient's residence and the
case reporting hospital, University of Nebraska Medical center (UNMC) was characterized as
short(<=12.5miles), intermediate (>12.5 to <50 miles) or long(>=50miles). The American Joint
Committee on Cancer (AJCC) the tumor-node-metastasis (TNM) staging 7th edition, was used
for staging of differentiated thyroid cancer. We dichotomized the stages as early (Stage I) and
late (stage II) for thyroid cancer patients' less than 45 years old. For patients over 45 years old,
we have dichotomized the stage as early (Stage I and II) and late (stage III, IV). Patients'
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demographics and clinicopathological features were compared between the Urban and Rural
populations using the chi-square test. We performed a multivariable logistic regression model to
look at the association factors between location of residence and outcome variable (stages of
thyroid cancer at diagnosis (early vs. late stage)), after adjusting for age at diagnosis and gender.
Results:
The odds of late-stage thyroid cancer diagnosis compared to early-stage diagnosis were 1.6 (95%
CI, 1.04 to 2.4) times higher among patients 45 years and older living in rural counties compared
to urban counties, after adjusting for age at diagnosis and gender (p=0.032).
Similarly, among patients 45 years and older, the odds of late versus early stage at diagnosis
were 2.0 (95% CI, 1.2-3.2) times greater for thyroid cancer patients living long distance (>= 50
miles) versus short distances (<= 12.5 miles) to the reporting hospital, after adjusting for age at
diagnosis and gender (p=0.01).
Conclusion:
Multiple studies have been conducted regarding racial disparities to improve its outcome among
various populations. However, the disparities of patients living in rural areas who face travel
burden and medical access to health that can affect thyroid cancer outcomes have been
overlooked. In our study, we found that patients 45 years and older living in rural areas and
longer distance from the diagnosing reporting hospital have higher odds of being diagnosed at
advanced stages of thyroid cancer compared to those living in urban areas.

INTRODUCTION
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BACKGROUND
Thyroid cancer is the most common endocrine malignancy which makes up 2.3% of newly
diagnosed cancer in the United States (US) with an estimated 43,800 new cases in 2022,
(Statistics of Thyroid Cancer (SEER, 2022), n.d.). Although incidence of thyroid cancer kept
increasing from 1995 to 2008, the incidence remained stable and plateaued between 2010-2019
((Statistics of Thyroid Cancer (SEER, 2022), n.d.) (Figure 2). This initial increase was
attributable to an increase in surveillance via use of more sensitive diagnostic modalities like
ultrasonography, computed tomography (CT) or Magnetic resonance imaging (MRI). Also, there
has been increased follow up surveillance of the incidental thyroid nodules (McDow et al.,
2020). The rising rate included multifactorial risks, including biological or genetic factors,
environment exposure, medical comorbidity, and lack of treatment adherence.
The incidence of thyroid cancer varies with age, gender, and race/ethnicity (Weeks et al., 2018).
20-49 years old Hispanic females had an increasing trend in incidence without deceleration after
2009, whereas elderly non-Hispanic white females had a decrease in incidence rate but stable
mortality rate (Kotwal et al., 2019). The incidence rate of Thyroid Cancer was 14.1 per 100,000
in 2014-2018, and the mortality rate was 0.5 per 100,000 in 2015-2019 (Key Statistics for
Thyroid Cancer (American Cancer Society, 2022)). Thyroid cancer rates in Nebraska (20142018) were comparable with US (2013-2017). Based on gender, incidence and mortality rate of
thyroid cancer was 23.6 and 0.3 per 100,000 females in Nebraska (2014-2018), 21.1 and 0.5 per
100,000 females in the US (2013-2017), 7.4 and 0.5 per 100,000 males in Nebraska and 7.3 and
0.5 per 100,000 males in US respectively (Table 8 and 9). Among males, whites have the highest
risk of getting thyroid cancer with an incidence rate of 7.5 per 100,000 compared to 6.8 per
100,000 in Asian and Pacific Islanders, 6.3 per 100,000 in Hispanics, and 3.3 per 100,000 in
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blacks and 3.3 per 100,000 in American Indian and islanders. Among female, incidence of
thyroid cancer is 9.7, 21.4, 21.2, 11.1 and 11.3 per 100,000 among white females, Asian and
Pacific Islander, Hispanic females, black females, and American Indian/Alaska Natives females
respectively (USCS Data Visualizations - CDC, 2022).
In Nebraska, despite 41.7% of thyroid cancer happened among age 45-64, 75% of death occurred
among 65 years and older (Figure 4, 5 and 6) (Department of Health et al., 2021). In US, thyroid
Cancer is most diagnosed among age groups 45-54 and 45-64 among all races and gender
(Department of Health et al., 2021)(Figure 3). Females are three times more likely to be
diagnosed with thyroid cancer (National Comprehensive Cancer Network, Guidelines for
Patients Details, 2022, n.d.). Radiation exposure to the head and neck at a young age and family
history of thyroid cancer or related syndromes (familial adenomatous polyposis (FAP) and
multiple endocrine neoplasia (MEN)) are common risk factors for developing thyroid cancer
(National Comprehensive Cancer Network, Guidelines for Patients Details, 2022, n.d.). In the
US, about 90% of thyroid cancers are papillary or follicular type, while anaplastic and medullary
cancers account for less than 5% (Siegel et al., 2022). Thyroidectomy with or without
postoperative administration of radioactive iodine therapy (RAI) represents the mainstay of
treatment of Differentiated Thyroid Cancer (Shah et al., 2017).
Social determinants of health care (SDHs) are defined as differences in the health outcomes among
specific populations (Gruszczynski et al., 2021). Disparities exist across the entire spectrum of
cancer care (cancer occurrence, diagnosis, treatment, prevention, and research participation). In
recent years, there has been a flood of research in cancer specialty on the new treatments from the
pharmaceutical industry and government-sponsored organizations which have led to an increase
in cancer survival, and quality of life. However, more studies are consistently describing a wider
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gap not only across racial/ethnic minorities but also in medically underserved populations
including those living in rural areas. Several studies recently have validated that underserved
populations are less likely to receive a standard of care recommended for the type and stage of
cancer. The consequential disparities can be minimized if we provide equitable access to the
standard of care. Hence, the complex mechanisms and systems that play a role in widening the
disparities among disadvantaged populations, must be addressed. Clinical interventions such as
social workers', establishing patient navigation system and use of local community leaders and
advocates via faith-based organizations (Churches) can reduce disparities (AACR Cancer
Disparities Progress Report 2022 | Cancer Progress Report, n.d.). Since 2009, the American
Society of Clinical Oncology (ASCO) has issued a policy statement on cancer care disparities and
also has updated 2019 statement to overcome long-standing disparities in cancer care. The
statement outlines both principles and recommendations with an effort to guide the future by
establishing a dedicated Health Equity committee which can foster awareness and address
inequities in access to care ("Erratum: Treatment of Locally Advanced Esophageal Carcinoma:
ASCO Guideline (American Society of Clinical Oncology (2020) DOI: 10.1200/JCO.20.00642),"
2020; Patel et al., 2020)
Much of the cancer studies related to inequalities have been descriptive. These have suggested that
thyroid cancer's racial/ethnic differences could have arisen from differential access to diagnostic
modalities like ultrasound guided or computed tomography (CT) fine needle aspiration (FNA), a
discrepancy in socioeconomic status, and differences in insurance coverage. Whites have higher
Age Adjusted Incidence Rate (AAIR) for Stage I and stage II cancers, whereas Asians and
Hispanics have significantly higher incidence for stages III and IV cancers (Weeks et al., 2018).
Young people have a low chance of dying from differentiated thyroid cancer (Thyroid Cancer
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Stages, American Cancer Society, 2022, n.d.). Risk factors for an adverse thyroid cancer outcome
include male sex, increased age, lymph nodes metastasis, large size tumors, and histologically
undifferentiated cancer, including medullary and anaplastic (Rose et al., 2013).
Although the cancer incidence rate declined similarly in metropolitan and rural areas, the cancer
mortality rate declined less in the rural populations (Hashibe et al., 2018). Observational studies
have reported higher incidence among urban residents compared to rural, affirming the concept of
epidemic of overdiagnosis than epidemic of the disease (Udelsman & Zhang, 2014). The existing
gap may depend on race, geography, health care access (availability and affordability of screening/
diagnosis and treatment), and education level (McDow et al., 2020) (Weeks et al., 2018).
Therefore, there have been substantial barriers to health care access among rural and urban
residents, which need further research to validate prior studies.
Cancer stage at diagnosis determines treatment options. Staging at diagnosis is a strong predictor
of survival (Lee et al., 2019; Statistics of Thyroid Cancer (SEER, 2022), n.d.). Thyroid cancer has
been grouped into localized, regional, and distant stages with 65.4% diagnosed at the local, 29%
at the regional and 3% at the distant stage where the cancer has already metastasized (Statistics of
Thyroid Cancer (SEER, 2022), n.d.). 5-year relative survival for localized, regional, and distant
metastatic type thyroid cancer are 99.9%, 98.3% and 53.3% respectively (Statistics of Thyroid
Cancer (SEER, 2022), n.d.). The American Joint Committee on Cancer (AJCC) TNM Staging 7th
ed. (2010), has defined thyroid cancer based on stages I (1) through IV (4), TNM system as the
extent of the tumor (T), spread to nearby lymph nodes (N) and to distant sites (metastasis) (M)
(Table A).
Table A: AJCC Prognostic Staging Groups (7th ed, 2010)
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AJCC Prognostic Staging

T

N

M

Stage I

Any T

Any N

M0

Stage II

Any T

Any N

M1

Stage I

T1

N0/Nx

M0

Stage II

T2

N0/Nx

M0

Stage III

T3

N1a

M0

Stage IVa

T4a

N1b

M0

Stage IVb

T4b

Any N

M0

Stage IVc

Any T

Any N

M1

Differentiated: Under 45 years

Differentiated: 45 years and older

Data on geographical disparities in the United States on thyroid cancer stages at diagnosis is
lacking, despite multiple studies. Descriptive studies conducted on thyroid cancer mainly
concentrated on race, gender, socioeconomic status, and stage at diagnosis.
We hypothesize that there is an association between urban and rural residence (exposure) and the
stage of thyroid cancer (outcome) at the time of diagnosis.
AIM: The primary purpose of this study is to identify the association between the urban/ rural
status of residence and stage of thyroid cancer at diagnosis. We also aim to identify an
association between a secondary exposure, the distance of patient residence from a health care,
with thyroid cancer stage at diagnosis.
HYPOTHESIS
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Null hypothesis: There is no difference in thyroid cancer diagnosis by stage in rural versus urban
residence.
Alternative hypothesis: The rural residents will have a more advanced stage of thyroid cancer at
the time of diagnosis than urban residents.

MATERIALS AND METHODS:
A retrospective cross- sectional study was conducted to assess the specific aims. In this study,
the integrated Cancer Repository for cancer research (iCaRe2) database was used to identify
patients diagnosed with primary thyroid cancer in the state of Nebraska, Iowa, North Dakota,
South Dakota, Kansas, and Missouri who presented to the University of Nebraska Medical
Center (UNMC) between (2000-2021). The iCaRe2 is a multi-institutional resource created and
maintained by the Fred and Pamela Buffett Cancer Center to collect and manage standardized,
multi-dimensional, longitudinal data and bio-specimens on consented adult cancer patients, highrisk individuals, and normal controls (The Integrated Cancer Repository for Cancer Research
(ICaRe2) - ICaRe2, n.d.). The database comprises many cancers in its registry and one of them is
Thyroid Tumor and Cancer Collaborative Registry (TCCR) which is the interest of our study. It
collects data on adults aged 19 years and older, diagnosed with Thyroid Cancer or Thyroid
Nodules. It includes data on socio-demographic characteristics, lifestyle, clinical data, quality of
life, medical history and family history of cancer and major diseases (Shats et al., 2016). The
county characteristics using Rural-Urban 2013 Continuum Codes (RUCC) and mapping between
FIFS and Zip codes with the population-based design used to categorize patients into rural and
urban residence. We have defined access to care by the distance to a medical facility. The
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distance between the participants' residence and the reporting hospital (UNMC) was classified as
short (<=12.5miles), intermediate (>12.5 to <50 miles) or long (>=50 miles).
UNMC IRB determined that the project does not constitute human subject research as defined in
45CFR46.102. Therefore, it is not subject to the federal regulations and does not require IRB
review.
Eligibility Criteria
We used the integrated Cancer data Repository for Cancer Research (iCaRe2) database to
identify patients who were diagnosed with primary thyroid cancer in the state of Nebraska, Iowa,
North Dakota, South Dakota, Kansas, and Missouri presented to the University of Nebraska
Medical Center (UNMC) between (2000-2021). Study participants are adults 19 years and older
who have provided consent to be enrolled into the TCCR (Shats et al., 2016; The Integrated
Cancer Repository for Cancer Research (ICaRe2) - ICaRe2, n.d.).
For this study, we have included differentiated thyroid cancer based on histological diagnosis
(papillary, follicular and hurthle cell origin). We have excluded undifferentiated thyroid cancers
(anaplastic and medullary type) and participants with missing data on county of residence. We
included 800 thyroid cancer patients who met the eligibility criteria for our study in the statistical
analysis (Figure 1).
Data Collection- The TCCR core data elements collected for thyroid patients include sociodemographic features like age, date of enrollment, age at diagnosis, county of residence, gender,
race/ethnicity, education, and household income (Shats et al., 2016; The Integrated Cancer
Repository for Cancer Research (ICaRe2) - ICaRe2, n.d.). Under lifestyle, tobacco/smoking
habits (ever smoker or never), alcohol consumption (current and past), lifestyle (dietary habits,
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vitamins/supplements intake, coffee drinking habits, physical activity, and sleep patterns) are
included. Under clinical data, first symptom, history of cancers, and major disease, surgical and
hospitalization history, imaging studies done, staging (pathological and clinical) histological
type, sites of involvement are also incorporated. Treatment (type, schedule, response), laboratory
test results, functional/medical changes after treatment, treatment outcome and vital status have
been included in the dataset and so in our study ((Shats et al., 2016; The Integrated Cancer
Repository for Cancer Research (ICaRe2) - ICaRe2, n.d.).

Figure 1. Framework of Study Population for TCCR Registry.
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iCaRe2, TCCR Registry, Year (2000-2021), Site (UNMC), States- Nebraska and the
neighboring states (Iowa, Kansas, Missouri, North Dakota, South Dakota).

STATISTICAL ANALYSIS
We assessed differences in patients' characteristics at diagnosis across geographic categories of
rural and urban using a chi-square test. Frequency and percentages for demographics, education,
lifestyle, and clinical characteristics were used to describe the categorical variables which are
shown in Table 2. We used a multivariable logistic regression model to look at the association of
location of residence and distance from hospital with the outcome variable, stage at diagnosis
while adjusting for age at diagnosis and gender. Our primary outcome is the stage at diagnosis.
The American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging 7th
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edition, was used for staging of differentiated thyroid cancer. Based on the staging criteria of
AJCC 7th edition, we created two groups from the total subject population- less than 45 years at
the diagnosis and 45 years and older. 1) In less than 45 years old, stage I is classified as early and
Stage II as late. 2) In 45 years and older group, the stage variable was dichotomized as early
(Stages I and II) and late (Stages III and IV). Crude (unadjusted) and adjusted odd rations (ORs)
and 95% confidence intervals (CIs) were reported to assess the association of predictor variables
and outcome variables. We considered a P value of <0.05 to be statistically significant for
analysis. Statistical analysis was done by using the SAS 9.4 version.

FOUNDATIONAL AND CONCENTRATION COMPETENCY
EPIMPH2 Apply appropriate study design and data collection methods to answer specific
epidemiology questions and address public health issues. Data was requested and collected from
iCaRe2(TCCR) registry, and an observational study was designed to see the geographical
disparity among thyroid cancer cases.
EPIMPH3 Analyze datasets using computer software. The descriptive statistics and the
association of predictor variables to outcome variables have been analyzed by using computer
software SAS version 9.4.
MPHF21 Perform effectively on an interprofessional team.
I have been communicating with my Capstone committee members through emails, zoom calls
to take their feedback regarding study design, statistical analysis. Their expertise has been
instrumental in the success of this project. This experience has provided me with the opportunity
to interact with my committee members on a professional level.
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RESULTS
The demographics and the clinicopathological features of total thyroid cancer patients were
analyzed and compared between rural and urban populations (Table A). Among 800 study
participants, 570 (71%) were urban, and 230 (29%) were rural residents.
The age at diagnosis was more frequent among age category 19-44 years in both urban and rural
residents, with statistical significance of p value =0.04. Participants were mostly of non –
Hispanic white race in both geographical locations, urban (89%), rural (98%). Thyroid cancer
patients were more likely to be female (76.2%) whole cohort. Obesity was slightly higher among
rural residents (50.4%) compared to urban residents (45.3%) but there was no statistical
difference between rural and urban populations while using BMI as a variable (p=0.18). Rural
residents had less college education (57.8%) than urban residents (47.1%) and was statistically
significant (p=0.02). Regarding smoking status, 40.3% of urban residents had ever smoked (over
100 cigarettes compared to 26.9% rural residents, however with statistical significance
(p=0.003). Overall, we found that 97.2% of patients had no distant metastasis. The distribution
was similar across rural and urban residents. The percentage of Thyroid cancer patients with
absent lymph nodes was higher among urban versus rural (66.2% vs 60%). The higher
percentage of tumor size (>4cm) in rural residents (31.05%) than urban residents (26.7%).
Majority of patients underwent total or near total thyroidectomy in both categories (71.1% in
urban and 64.3% in rural) and there was no statistically significant difference between and
followed by Radioiodine ablation therapy was more common in rural residents (55.9%)
compared to urban population (52.9%).
Thyroid cancer has a very good prognosis with over 98% survival. The prognosis is more
favorable in <45 years than higher ages in previous study and registries. AJCC 7 prognostic
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staging is also different based on age with age < 45 years vs in 45 years and above. So, to avoid
any skewed results, we analyze our hypothesis separately in these 2 different cohorts- age under
45 years and age 45 and above.
The demographics and clinicopathological features of Thyroid Cancer patients for < 45 years old
groups were compared between Urban and Rural populations (Table 1). Among 388 study
participants, 290 (74.7%) were Urban and 98 (25.26%) were rural residents. Thyroid Cancer
patients were more likely to be female (82.2%). Participants were mostly of white race in both
geographical locations-urban (90.6%), rural (95.7%). Rural residents had less college education
(48.6%) than urban residents (38.9%) with 25% missing data on education. Regarding smoking
status, 35.3% of urban residents had ever smoked (over 100 cigarettes) compared to 23.53%
rural residents. Also, there were 40% of data missing regarding smoking status. Obesity was
higher among rural residents (49.4%) compared to urban residents (41.2%) and was the only
variable that had a statistically significant difference between rural and urban populations under
the 45 years cohort (p =0.04). Race, gender, education type and smoking variables were not
statistically significantly different when compared to rural versus urban (p=> 0.5) (Table 1)
Overall, we found that 96% of patients were diagnosed at an early stage (Stage I), and only 4%
were diagnosed at a late stage. Also, most patients were in the early stage in both cohorts (96%
in urban and 95% in rural) and were not statistically significantly different among rural and
urban residents. Most patients underwent total or near-total thyroidectomy in both categories
(72.9%) in urban and 63.3% in rural). The percentage of Thyroid Cancer patients with absent
lymph nodes was higher in both urban and rural residents (60% vs 55%). Overall, we found that
97.35% of patients had no distant metastasis. The distribution was similar across rural and urban
residents (Table 1).
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TABLE A: Demographics and Clinicopathological variables of total thyroid cancer
patients' vs urban vs rural cohort
Variables

Urban,

Rural,

Total,

N (%) 570(71.25) N (%) =230(28.7) N (%) =800(100%)
Age at Diagnosis

P
value

0.04

19-44 years.

290(50.8)

98(42.6)

388(48.5)

45-64years

212(37.1)

92(40.0)

304(38.0)

65-95 years

68(11.9)

40(17.3)

108(13.5)

506 (89.2)

222 (97.8)

728 (91.8)

Others

61 (10.7)

4 (1.8)

65 (8.1)

Missing

3

4

7

Race
Non-Hispanic
whites

Gender

0.16

Female

427(74.9)

183(79.5)

610(76.2)

Male

143(25.09)

47(20.43)

190(23.7)
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BMI

0.18

Normal

138(25.3)

41(19.16)

179(23.5)

Overweight

160(29.3)

65(30.3)

225(29.6)

Obese

247(45.3)

108(50.4)

355(46.7)

Missing

15

16

41(5.1)

Education

0.02

Graduate

115(28.2)

41(27.8)

156(28.1)

College Graduate

100(24.5)

21(14.29)

121(21.8)

Less college

192(47.1)

85(57.82)

277(50.0)

Missing

163

83

246(30.7)

Smoking

0.003

Ever Smokers

152(40.3)

36(26.09)

188(36.5)

Never Smokers

225(59.6)

102(73.9)

327(63.5)

Missing

193

92

285(35.6)

Metastasis

0.14

No

525(97.7)

208(95.8)

733(97.2)

Yes

12(2.23)

9(4.15)

21(2.79)

18
missing

33

13

46(5.7)

Lymph Node

0.2

Absent (NO)

365(66.2)

136(60.1))

501(64.4)

Central(N1a)

99(17.9)

47(20.8)

146(18.7)

Lateral(N1b)

87(15.7)

43(19.0)

130(16.7)

Missing

19

4

23(2.8)

Tumor size

0.3

0.1-2.0(T1)

284(52.0)

101(46.1)

385(50.3)

2.1-4 (T2)

116(21.2)

50(22.8)

166(21.7)

>4.0 (T3/T4)

146(26.7)

68(31.05)

214(27.9)

Missing

24

11

35(4.3)

Procedure type
Total/near total

0.1
379(71.1)

130(64.3)

509(69.2)

Lobectomy

120(22.5)

58(28.7)

178(24.2)

Others

34(6.3)

14(6.9)

48(6.53)

Missing

37

28

65(8.1)

thyroidectomy

19
Therapy type

0.45

RAI therapy/1131

292(52.9)

122(55.9)

414(53.8)

Others

259(47.0)

96(44.0)

355(46.1)

Missing

19

12

31(3.8)

b

Body mass index (BMI) <18.5kg/m2 was defined as underweight, BMI between 18.5and 24.9kg/m2 was defined as
normal, BMI between 25-29.9kg/m2 as overweight and BMI>=30kg/m2 as obese (CDC,2017). excluded
underweight BMI due to a very low sample.
c

smoking status was based on patients who had smoked over 100 cigarettes in their lifetime

d

from the chi-square test

TABLE 1: Characteristics of patients within subgroups (age < 45 years = 19-44 years)
Variables

Urban,
Rural,
Total,
N(%)=290(74.7) N(%) =98(25.26 N (%)=388(100%)

Gender

P value
0.17

Female

234(80.69)

85(86.73)

319(82.2)

Male

56(19.31)

13(13.27)

69(17.7)
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Race
White

262 (90.6)

91 (95.7)

353(91.9)

Black/African
Americans

6(2.08%)

1 (1.05)

7(1.8)

Others

20(6.8)

3 (3.25)

23(5.9)

Missing

2

3

5(1.2)

b

0.04

BMI
Normal

91(32.3)

18 (18)

109(28.9)

Overweight

74(26.3)

30(31.5)

104(27.6)

Obese

116(41.2)

47(49.4)

163(43.3)

Missing

9

3

12

Education

0.05

Graduate

61(27.9)

10(13.89)

71(24.4)

College
Graduate

72(33.3)

27(37.5)

99(34.1)

Less college

85(38.9)

35(48.6)

85(38.9)

Missing

72

26

98(25)

c

0.07

Smoking
Ever Smokers

71(35.3)

16(23.53)

87(32.3)

Never Smokers

130(64.6)

52(76.4)

182(67.6)

Missing

89

30

119(31)

21

22

Notes.
b

Body mass index (BMI) <18.5kg/m2 was defined as underweight, BMI between 18.5and 24.9kg/m2 was defined as
normal, BMI between 25-29.9kg/m2 as overweight and BMI>=30kg/m2 as obese (CDC,2017). excluded
underweight BMI due to a very low sample.
c

smoking status was based on patients who had smoked over 100 cigarettes in their lifetime

d

from the chi-square test

Table 4: Characteristics of patients within subgroups (Equal to or above 45 Years age)

Variables.
Diagnosis age
45-64 years
65-95 years
BMIb
Normal
Overweight
Obese
Missing
Gender
Female
male
Race
White
African Americans
Others
Missing
EDUCATION
Graduate
College graduate
Less college
Missing
AJCC 7 Stage
Early: Stage (I, II)
Late: Stage (III,
IV)
Missing
Procedure type

Urban
N=280 (67.9%)

Rural
N=132 (32.04%)

Total
N=412 (100%)

P Valued
0.19

212 (75.7)
68 (24.2)

92 (69.7)
40 (30.3)

304 (73.7%))
108 (26.2)

47 (17.8)
86 (32.5)
131 (49.6)
16

23 (19.3)
35 (29.4)
61 (51.2)
13

70 (18.2)
121 (31.5)
192 (50.1)
29

193 (68.9)
87 (31.07)

98 (74.2)
34 (25.7)

291 (70.6)
121 (29.3)

244 (87.7)
24 (8.6)
10 (3.6)
2

131 (99.9)
1 (0.76)
0

375 (91.4)
25 (6.10)
10 (3.6)
2

0.8

0.26

0.3
39 (20.6)
43 (22.7)
107 (56.6)
91

11 (14.6)
14 (18.6)
50 (66.6)
57

50 (18.9)
43 (22.7)
107 (56.6)
148 (36)
0.034

156 (58.2)
112 (41.7)

59 (46.8)
67 (53.1)

215 (54.57)
179 (45.43)

12

6

18
0.23

23
Total/near-total
thyroidectomy
lobectomy
others
missing
Therapy Type
RAI therapy/I131
Others
Missing
Smokingc
Ever smokers
Never smokers
missing
Tumor size
0.1-2.0 cm(T1)
2.1-4.0cm(T2)
>4cm(T3/T4)
missing
Lymph Nodes
Absent (No)
Central neck (N1a)
Lateral neck (N1b)
Missing
Distant
metastasis
No
Yes
Missing
Distance to center
Short<=12.5 miles
Intermediate>12.5<50 miles
Long>=50miles

181 (70.7)

69 (63.3)

250 (68.49)

56 (21.88)
19 (7.4)
24

33 (30)
7 (6.42)
23

89 (24.3)
26 (7.12)
47 (11)
0.27

116 (42.9)
154 (57.7)
10

61(48.8)
64(51.2)
7

177(44.8)
218(55.1)
17
0.01

81 (46.02)
95 (53.9)
104

20 (28.5)
50 (71.4)
62

101 (41.06)
145 (58.9)
166 (40)

147 (55.06)
52 (19.4)
68 (25.4)
13

53 (42.4)
29 (23.2)
43 (34.4)
7

200 (51.0)
81 (20.6)
111 (28.3)
20

196 (72.5)
35 (12.9)
39 (14.4)
10

83 (64.34)
23 (17.8)
23 (17.8)
3

279 (69.9)
58 (14.5)
62 (15.5)
13

0.05

0.23

0.1
253 (96.5)
9 (3.4)
18

112 (93.3)
8 (6.67)
12

365 (95.5)
17 (4.45)
30
<.0001

187 (66.7)
53 (18.93)

0
16 (12.1)

187 (45.3)
69 (16.7)

40 (14.2)

116 (87.8)

156 (37.86)

b

Body mass index (BMI) <18.5kg/m2 was defined as underweight, BMI between 18.5and 24.9kg/m2 was defined as
normal, BMI between 25-29.9kg/m2 as overweight and BMI>=30kg/m2 as obese (CDC,2017). excluded
underweight BMI because of a very low sample.
c

Smoking status was based on patients who had smoked over 100 cigarettes in their lifetime

d

from the chi-square test

Table 4 shows the demographics and clinicopathological features of Thyroid Cancer patients for
45 years and older groups, which were compared between Urban and Rural populations. Among
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412 study participants, 280 (67.9%) were Urban and 132 (32.04%) were rural residents. The age
at diagnosis was more frequent among age category 45-64 years in both urban and rural
residents. Thyroid Cancer patients were more likely to be female (70.6%). Participants were
mostly of white race in both geographical locations-urban (87.7%), rural (99.9%). Obesity was
slightly higher among rural residents (52%) compared to urban residents (49.6%) but there was
no significant difference between rural and urban populations while using BMI as variable (p
=0.8). Rural residents had less college education (66.6%) than urban residents (56.6%).
Overall, we found that 54.5% of patients were diagnosed at an early stage, being 46.8% in rural
counties and 58.2% in urban counties. Rural residents were more likely to be diagnosed at late
stage (III, IV) (53.1%) of thyroid cancer at the time of diagnosis than urban residents (41.7%)
and were statistically significant (p = 0.034). Majority of patients underwent total or near-total
thyroidectomy in both categories (70.7% in urban and 63.3% in rural) and there was no
significant difference between rural and urban populations by procedure type (p=0.23).
Radioactive iodine therapy was more common in the rural population (48.8%) compared to the
urban population (42.9%). Regarding smoking status, 46.0% of urban residents had ever smoked
(over 100 cigarettes) compared to 28.5% of rural residents (p =0.01). However, there was 40% of
data missing regarding smoking status. We found a higher percentage of tumor size (>4cm) in
urban residents (34.4%) than rural residents (25.4%). The percentage of Thyroid Cancer patients
with absent lymph nodes, was higher among urban versus rural residents (72.5% vs 64.3%).
Overall, we found that 95.5% of patients had no distant metastasis. The distribution was similar
across rural and urban residents. In addition, rural residents were more likely to be living long
distances (87.8%) from the reporting hospital compared to urban counterparts (14.2%) and were
statistically significant (p<0.0001).

25

Table 5: Factors associated with late-stage diagnosis in multivariable Logistic Regression
analysis (45 years and older at the time of diagnosis)
Rural/Urban
Category

Significant
Variables

Unadjusted,
OR (95%CI)

P value Adjusted OR
(95% CI)

Urban

Reference

Rural

1.5 (1.03-2.42) 0.034

1.6 (1.04-2.4)

P* value

0.032

Gender
Male

Reference

Female

0.56 (0.36-0.8) 0.009

0.53 (0.34-0.8) 0.005

Age at
Diagnosis
65-95 years

Reference

45-64 years

0.55 (0.3-0.8)

0.010

0.56 (0.350.89)

0.014

*

Analyses were adjusted for diagnosis age, gender.

Abbreviations: CI confidence interval; OR odds ratio.

The odds ratio (OR) of a late versus early stage at diagnosis (Stage III, IV versus I and II) was
1.6 with a 95% confidence interval (CI) between 1.04 to 2.4 p=0.032 (Table 5) among rural
residents than urban in 45 years and older patients with a diagnosis of thyroid cancer. So, age 45
year and older and living in rural counties have 60% more likely to be diagnosed at a late-stage
than those living in urban counties, after adjusting for age at diagnosis and gender.
Odds of late-stage thyroid cancer versus early-stage were 0.53 times (or 47%) lower among
females than males. Also, the odds of late-stage thyroid cancer for age 45-64 years were 0.56
times (or 44%) lower than those diagnosed at age 65 to 95 years.
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However, Body Mass Index (BMI) was not associated with the log odds of being diagnosed at
late-stage thyroid cancer in a multivariable logistic regression model with p value=0.06 (Table
B).
Table B: Analysis of Maximum Likelihood Estimates
Parameter

Estimate

Standard Error

P value

Intercept

0.099

0.43

0.5

RU2013_CAT

Rural

0.21

3.3

0.06

AGEGRP

45-64

-0.28

0.12

0.03

GENDER

Female

-0.3

0.11

0.008

BMI

Normal weight

-0.01

0.19

0.94

BMI

Obese

0.27

0.14

0.06

The change in estimate (CIE) =0.23 (adjusted effect)-0.22 (unadjusted effect)/0.23=0.04% which
is less than 10%. So, age at diagnosis and gender are not confounders.
The p value for the interaction term (rural * (45-64) years is not significant (p=0.29). So, there is
no interaction between rural and age group. The p value for the interaction term (female * rural)
is also not significant (p value=0.10). So, there is no interaction between rural and female.

Table 6: Association between distance from medical facility subgroups and Late stage at
diagnosis (stage III and IV) in multivariable Logistic Regression analysis (for 45 years and
over at the time of diagnosis).
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Distance to Center

Significant
Variables

Unadjusted
OR (95%CI)

Short<=12.5miles

Reference

Long>=50miles

1.9 (1.2-3.0)

P
Adjusted a OR
value (95%CI)

P
*value

0.02

0.01

2.0 (1.2-3.2)

Gender
Male

Reference

Female

0.56 (0.360.8)

0.009 0.50 (0.310.79)

0.0036

0.010 0.58 (0.350.95)

0.032

Age at
Diagnosis

a

65-95

Reference

45-64

0.55 (0.3-0.8)

Analyses were adjusted for diagnosis age, gender.

Abbreviations: CI confidence interval; OR odds ratio.

The odds of a late stage at diagnosis were 2.0 (95% CI, 1.2-3.2) times greater for thyroid cancer
patients living long distance (>= 50 miles) to the reporting hospital as compared to short distance
(<=12.5miles) after adjusting for age and gender (Table 6). Odds of late-stage thyroid cancer
versus early-stage were 0.50 times (or 50%) lower among females than males. Also, the odds of
late-stage thyroid cancer for age 45-64 years were 0.58 times (or 42%) lower than those
diagnosed at age 65 to 95 years.

DISCUSSION

This study found that the patients who were diagnosed with a thyroid cancer at 45 years of age
and over, at the time of diagnosis and living in rural geography, have a higher risk of diagnosing
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at the late-stages (stages III and IV) of thyroid cancer based on AJCC 7th edition classification as
compared to those living in urban areas. The odds of diagnosing late-stage thyroid cancer were
1.6 times higher among patients living in rural counties compared to urban counties, after
adjusting for age at diagnosis and gender, with a 95% confidence interval (CI) between 1.04 to
2.4. Also, the patients living over 50 miles from the medical facility had higher odds of being
diagnosed with late-stage thyroid cancer than those living within 12.5 miles at the time of
diagnosis.
Our study confirmed the disparities at the stage of diagnosis on geographic boundaries for
thyroid cancer. Patients living in rural areas will probably face travel burdens (long distance to
travel, require time off from their work, or accommodation issue) which will affect their medical
access and the ultimate outcome. Similar disparities were reported across other cancer spectrum
(Johnson et al., 2021). However, Johnson et al. reported the study on five different cancers,
including thyroid cancer. A systematic meta-analysis suggested that breast cancer patients had
1.19 times the odds (95% CI, 1.12-1.27) of late-stage diagnosis among those residing in rural
compared to urban areas (Nguyen-Pham et al., 2014). Similarly, Segel at al. reported a lower rate
of early-stage pancreatic cancer at diagnosis in rural counties (Segel et al., 2020).
Disparities in stage at diagnosis across the geographical boundaries were also reported outside of
the United States (US) across five most common cancers (lung, stomach, colorectum, esophagus,
breast cancers) in an observational study conducted in China by Zeng et al. The persistent
diagnostic disparity was demonstrated between rural and urban areas (Zeng et al., 2021).
Our multivariate analysis of thyroid cancer patients also revealed that women were 47% less
likely to be diagnosed with late-stage thyroid cancer compared to men who are residing in rural
areas. Weeks et al. in their study identified that women with thyroid cancer are diagnosed with
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small tumors (< 4 cm). Similarly, an adverse thyroid cancer outcome to male sex, increased age,
lymph nodes metastasis, large size tumors, and histologically undifferentiated cancer, including
medullary and anaplastic, has been reported (Rose et al., 2013). Women were found to have
frequent healthcare providers visits and receive frequent check-ups more often than males and
may constitute an early diagnosis of smaller size tumor (Weeks et al. 2018). However, our study
did not show any significant outcome based on tumor size and lymph node metastasis.
From the thyroid cancer registry in Nebraska (2014-2018), the incidence of thyroid cancer in
females was 23.6 per 100,000 and 7.4 per 100,000 for males in the state of Nebraska (Table 9)
(Department of Health et al., 2021). Similarly, our study population also has a higher percentage
of females, so further investigation is needed to better understand higher incidence among
females in relation to medical access versus biological, hormonal, or genetic factors.
Beyond 55 years, there are increasing trends in the case fatality rate (Mazurat et al., 2013). So,
increasing age is associated with both increased recurrence and mortality of thyroid cancer. Our
multivariable analysis found that thyroid cancer patients for those aged 45 to 64 years were less
likely to be diagnosed at a late stage compared to 65 to 95 years. Prior studies on welldifferentiated thyroid cancer with regional or distant metastasis have a survival rate dependent on
age (Haymart, 2009; Mazurat et al., 2013).
Under the 45 years of age cohort, rural residents and those living long distance from the medical
facility were not associated with late-stage diagnosis for thyroid cancer. However, under 45, we
found that 96% of patients were diagnosed at an early stage (Stage I), and only 4% were
diagnosed at late stage (stage II). Also, most patients were in the early stage in both cohorts
(96% in urban and 95% in rural) and were not statistically significant. So, further analysis was
not done, and would likely skew due to very small sample size in the late stage. Thyroid cancer
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patients under 45 years can have distinctly different prognosis than those aged 45 years and over.
Henceforth, age is an important prognostic marker for well -differentiated thyroid cancer. Studies
have shown that patients aged 20-44 years have a low risk of tumor recurrence and a low risk of
overall mortality (Haymart, 2009).
We have found the higher percentage of rural residents were obese than urban residents among
<45years old. The nationally representative cross-sectional sample studying rural/urban
disparities showed that the odds of obesity were higher in rural compared to urban areas (odds
ratio=1.3, p<.001). In addition, Masone et al., suggested that obesity and excess body weight
were related to increased risk of thyroid cancer (Masone et al., 2021).
Regarding geographic differences in thyroid cancer incidence and survival, McDow showed both
a higher incidence and long-term survival for thyroid cancer in urban areas compared to rural
areas (McDow et al., 2020). Considering high survival rates in thyroid cancer, approaching 98%,
we opted not to consider the survival in our current study. However, this can be a topic of future
investigation and would probably need a larger sample size.
In thyroid cancer, tumor size and histology differed significantly among race and insurance status,
with non-white being less associated with small sized thyroid cancer compared to white
population. Similarly, medicaid and uninsured patients were less associated with thyroid cancer
less than 4 cm and papillary type (Weeks et al., 2018).
Even though overall survival of thyroid cancer is much more favorable than other cancer types,
our study reinforces the need for better access to healthcare, especially for elderly and rural
populations, so that thyroid cancer can be diagnosed and treated at an early stage before it
progresses. Through our study, we realized that living in a rural area is an independent predictor
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of diagnosis at a later- stage of thyroid cancer. Also, male sex, and age group 65 and over have
independent risk factors for diagnosing at a later stage, which will probably affect the outcomes.
This suggests that further research will be needed on factors affecting the early diagnosis of thyroid
cancer beyond access to care.

Limitation

This study is an observational study. So future studies are needed to explore whether the
association between the independent covariates and the stage at diagnosis determine causality.
This cancer registry only represents the patients that are being seen at UNMC, a single medical
center in the state of Nebraska, with some referral from neighboring states (Iowa, Kansas,
Missouri, North Dakota, South Dakota). This is not a representation of all thyroid cancers in the
state of Nebraska, and/ or neighboring states. So, we cannot generalize the findings from our
study to the entire Nebraska state population or the US populations.
We didn't incorporate education and smoking in the multivariable regression model because over
20% of data were missing, and it will probably skew the results. However, prior studies have
shown that cigarette smoking was associated with decreased risk of incidence of thyroid cancer
in men but not in women (Cho et al., 2018).
When examining thyroid cancer incidence trends in Surveillance Epidemiology and End Results
(SEER), high income counties have experienced high thyroid cancer incidence because of
advancement of diagnostic technologies like USG guided Fine needle aspiration cytology
(FNAC), access to MRIs leading to more biopsies among those who are rich. However, the
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confounding association with education and socioeconomic status may coexist and can be a topic
of research in the future.
Other barriers for disparities in thyroid cancer that were not considered in this study included
ethnicity or race. TCCR registry represents only English-Speaking residents and exclusively 90%
of the registry were non-Hispanic whites. Thyroid cancer incidence trend still increasing in
young Hispanic and Black, although overall trend plateaued, and further deceleration appeared in
non-Hispanic Whites and elderly (Kotwal et al., 2019).
Our study confirmed that the patients living over 50 miles from the medical access had an
increased likelihood of presenting at late-stage thyroid cancer. In the future, we can further
categorize each patient's residence by metro, non-metro (adjacent to population >=200,000),
small rural town and isolated rural town and can further quantify the nature and magnitude of
disparities.
In this study, we use the American Joint Committee on Cancer (AJCC) TNM staging 7th edition
for patients with differentiated thyroid Cancer. We have included patients who are diagnosed
with thyroid cancer since 2000, when staging was done using AJCC 7th edition. However, from
2018, the American Joint Committee on Cancer (AJCC) 8th edition has been in practice. One of
the population-based retrospective reviews showed that 20% of patients were downstage from
the 7th edition to the 8th edition. (Gan et al., 2019). It would be interesting to do a similar study
with the AJCC 8th edition in the future and see if the association with rural/urban disparity still
exists regarding the stages of thyroid cancer.

Conclusion:
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Our study results show that rural residents and residents living a long distance from reporting
medical facilities are associated with later stages of diagnosis. Being male sex and age above 65
have increased chances of thyroid cancer diagnosis at a later stage. Health disparities will further
exacerbate the differences in outcome of cancer across the disadvantaged populations (rural
residents) and hence, geography will continue to affect cancer outcomes.
This study will open a public health, social and political discussion to consider prioritizing and
allocating more resources in the disparities areas, including building a new health facility or
preventing closure of existing facilities via the state and federal public health policies.
Implementation of strategies that use patient navigation, faith-based organization (churches) and
local community engagement, and social services can improve health access and will reduce
disparities.

Figure 2. New cases and Deaths of thyroid cancer in the US. 1975-2020
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(Statistics of Thyroid Cancer (SEER, 2022), n.d.)

Table 8. Cancer incidence in Nebraska (2014-2018) and US (2013-2017)
NEBRASKA (2014-2018)
Male

US 2013-2017

Female

Total

Male

Female Total

No

Rate

No

Rate

No

Rate

Rate

Rate

Rate

All sites

26,447

509.1

24,893

440.5

51,341

468.0

488.5

422.2

448.7

Thyroid

370

7.4

1,116

23.6

1,486

15.4

7.3

21.1

14.3

cancer
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Nebraska cancer registry, 2021
Table 9. Cancer mortality in Nebraska (2014-2018) and the U.S(2013-2017)
NEBRASKA (2014-2018)
Male

All

US (2013-2017)

Female

Total

Male

Female Total

No

Rate

No

Rate

No

Rate

Rate

Rate

Rate

9,138

182.8

8,226

132.9

17,364

154.1

189.5

135.7

158.3

0.5

20

0.3

44

0.4

0.5

0.5

0.5

sites
Thyroid 24
cancer
Nebraska cancer registry, 2021(Department of Health et al., 2021)
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Figure 3. Age distribution of thyroid incidence in the United States.
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Figure 4.

Age distribution of thyroid cancer incidence Nebraska
(2014-2018)
45.00%
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35.00%
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20.00%
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10.00%
5.00%
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18-44
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45-64
65 and older
Percent of thyroid cancer

0-17
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Figure 5. Percent of death by age group: Thyroid Cancer (US)

Statistics of Thyroid Cancer (SEER, 2022), n.d.)
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Figure 6. Percent of death by age group: Thyroid Cancer, Nebraska (2014-2018)

80%
70%
60%
50%
40%
30%
20%
10%
0%
0-17

18-44

45-64

65 and older

Nebraska cancer registry, 2021
Figure 7. Percentage of Thyroid cancer and 5-year relative survival by stage at diagnosis
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Statistics of Thyroid Cancer (SEER, 2022), n.d.)

(Statistics of Thyroid Cancer (SEER, 2022), n.d.)
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